Navigation Links
Divergence Raises $11.8 Million in Series C Financing
Date:2/11/2009

ing investors, provides further validation of Divergence's revolutionary technology and the rapid advancements of our projects in parasite control," said Derek K. Rapp, Chief Executive Officer of Divergence. "Through our internal programs and corporate alliances in crop protection and animal health, Divergence is committed to the development of parasite control products for higher yielding agriculture and healthier people and animals. Upon the completion of this financing, Ronald L. Meeusen, Ph.D., Partner of Midpoint Food & Ag Fund, LP, will join the Divergence Board of Directors. Dr. Meeusen brings to Divergence more than 25 years of corporate experience in agricultural biotechnology. "There is tremendous value in the cutting-edge science of Divergence," said Dr. Meeusen. "As the first company in our investment portfolio, Divergence exemplifies our goal to invest in companies that can enable environmentally sustainable agriculture and offer promise for human and animal wellness."

With the addition of Dr. Meeusen, the Board of Directors of Divergence stands at seven people - Stanford J. Goldblatt, Partner and Head of the Private Equity Practice at Winston & Strawn; James P. McCarter, M.D., Ph.D., President and Chief Scientific Officer of Divergence; John W. McCarter, Jr., President and CEO of the Field Museum in Chicago; Ronald L. Meeusen, Ph.D., Partner of MidPoint Food and Ag Fund, LP; Ilya B. Nykin, Managing Director of Prolog Ventures; Derek K. Rapp, Chief Executive Officer of Divergence; and Mark W. Wong, President and CEO of Agrivida, Inc.

About Divergence:
Divergence, Inc., a world leader in the application of genomics and informatics to agriculture and infectious disease, discovers and develops products for the safe and effective control of parasites. The company's initial focus is on parasitic nematodes, devastating unseen pests that cause billions of dollars in crop loss annually and wides
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
2. AMERIGROUP Praises Expansion of State Childrens Health Insurance Program (SCHIP)
3. JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism
4. Anacor Raises $50 Million in Equity Financing
5. MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile
6. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
7. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
8. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
9. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
10. China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income
11. MacroGenics Raises $25M in Series D-2 Financing
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Divergence Raises $11.8 Million in Series C Financing
(Date:9/18/2014)... , Sept. 18, 2014 About ... testing, is performed outside a clinical laboratory. It ... in administrating appropriate treatments and medication. POCT is ... prevalence of lifestyle diseases such as diabetes, heart ... user-friendly. POCT devices are standardized to minimize errors ...
(Date:9/18/2014)... Station, Texas (PRWEB) September 18, 2014 ... System Chancellor John Sharp, Texas A&M Health Science ... the U.S. Department of Health and Human Services ... today dedicated a national pandemic influenza vaccine manufacturing ... serve as an anchor for the Texas A&M ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ ... report to their offering. The ... a CAGR of 22.7% from 2014 to 2019. Factors ... treatment, growing adoption of companion diagnostics by the pharmaceutical ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... Bavituximab, Currently in Phase II Cancer Trials in Combination with ... Chemotherapy -, ... ... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing monoclonal antibodies for ...
... design offers enhanced convenience, ease-of-use, and helps optimize ... ... March 3 Metrex Research Corporation is,pleased to announce the newest ... unique patented design offers a new,easy-open/easy-close pull tab with slim, flexible ...
... Disposables, Services and Accessories Revenue Up 102% ... ST. LOUIS, March 3 Stereotaxis, Inc. (Nasdaq:,STXS) ... full year,ended December 31, 2007., For the full ... $27.2 million in 2006. Sales of the Niobe(TM) system ...
Cached Biology Technology:Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 2Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 3Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 4Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 5CaviWipes(R): Taking Surface Disinfection to a New Level 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 3Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 4Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 6Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 7Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 8Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 9Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 10
(Date:9/18/2014)... small, icy moon of Uranus, is one of the ... system. Despite its relatively small size, Miranda appears to ... in the formation of at least three remarkable and ... , These coronae are visible in Miranda,s southern hemisphere, ... Arden corona, the largest, has ridges and troughs with ...
(Date:9/18/2014)... can operate inside the bore of an MRI scanner ... research partnership program at Brigham and Women,s Hospital in ... in conjunction with real-time MRI images, can make prostate ... discomforting for the patient. The novel system also has ... precision. , Developed by a team of robotics engineers ...
(Date:9/18/2014)... the International Space Station ever starts a "frequent flyers" ... status. Recently the orbiting laboratory has hosted increasing numbers ... returned from the space station in April, and another ... third experiment is planned to launch in December. , ... around the world-- and in space. Model organisms can ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... For the first time, a study by researchers at Columbia ... post-traumatic stress disorder (PTSD) among adults. The study of male ... the association between asthma and PTSD is not primarily explained ... twin pairs, who had lived together in childhood, and who ...
... N.Y. Single-molecule biologythe revolutionary field that deals ... Tremendous technical advances have made it possible to ... images as they twist, twirl, wobble, and unfold. ... book that was just released by Cold Spring Harbor ...
... MADISON - When University of Wisconsin-Madison researchers succeeded in ... they also began to redefine the political and ethical ... Alta Charo, a UW-Madison professor of law and bioethics, ... the social dimensions of the ongoing controversy over embryonic ...
Cached Biology News:Asthma link to post-traumatic stress disorder, says Mailman School of Public Health study 2New book presents methods to poke and prod individual molecules 2Reprogramming the debate: stem-cell finding alters ethical controversy 2Reprogramming the debate: stem-cell finding alters ethical controversy 3
... Immunogen: Synthetic peptide derived from an ... mTOR (Mammalian target of rapamycin FRAP RAFT1 ... mTOR protein. On Western blots it ... Reactivity: Human (positive control: HEK293 cell ...
MW5...
... Intended to qualitatively ... in formalin-fixed, paraffin-embedded (FFPE) ... spreads, and cell preparations, ... Hybridization (CISH). Fluorescent In ...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Biology Products: